Self-concept and Engagement in LiFe (SELF): A waitlist-controlled pilot study of a novel psychological intervention to target illness engulfment in enduring schizophrenia and related psychoses.

BACKGROUND: Illness engulfment, a process whereby one's self-concept becomes defined entirely by illness, is implicated in the association between insight and depressive symptomatology in schizophrenia. We examined the feasibility and acceptability of a brief intervention called Self-concept and Engagement in LiFe (SELF) that aims to reduce engulfment and enhance personal recovery. METHODS: Forty individuals diagnosed with schizophrenia spectrum disorders were assigned to SELF intervention or waitlist-control (treatment-as-usual). Outcome measures included the Modified Engulfment Scale and measures of depressive symptomatology, self-esteem, recovery style, quality of life, and self-stigma. RESULTS: Retention at post-therapy was 90% (18/20 completed SELF; 18/20 remained on waitlist). Eleven waitlist participants then completed SELF (73% overall retention). Participants reported high satisfaction with the intervention, and participation was associated with reduced engulfment (ES = 0.48), more adaptive recovery style (ES = 0.37), improved self-esteem (ES = 0.35), and reduced self-stigma (ES = 0.25). The treatment group had lower engulfment (adjusted mean = 91.9) compared to waitlist (adjusted mean = 100.0) post-therapy, F (1,32) = 5.78, p = .02, partial η2 = 0.15. CONCLUSIONS: The SELF intervention is highly acceptable to participants and can reduce engulfment and improve secondary outcomes. Future research should examine the efficacy of SELF in a larger randomized controlled trial.

The role of illness engulfment in the association between insight and depressive symptomatology in schizophrenia.

Good clinical insight in schizophrenia tends to be associated with better outcomes, but also with increased depression. We hypothesized that illness engulfment, a process whereby an individual's self-concept becomes defined solely by illness and the 'patient identity' becomes primary, is a mediating and/or moderating factor in the association between insight and depressive symptomatology in schizophrenia. Mediation and moderation analyses were conducted using the PROCESS macro on data from 140 individuals with enduring schizophrenia who completed measures of the insight dimension of 'Awareness of Illness and Need for Treatment' (AINT), the Calgary Depression Scale, and the Modified Engulfment Scale. There was a significant indirect effect of AINT, mediated through engulfment, on depressive symptomatology (95% CI = 0.017 to 0.143), independent of duration of illness and current severity of positive symptoms. Moderation analysis revealed a significant interaction effect between level of engulfment and AINT, on depressive symptomatology, b = 0.005, t (134) = 2.814, p < .01, 95% CI = 0.002 to 0.009, controlling for the duration of illness and current severity of positive symptoms. At low levels of engulfment, higher AINT was associated with lower depression scores; while at high levels of engulfment, higher AINT was associated with higher depression scores. Illness engulfment may be an important process by which insight influences mood in schizophrenia. Insight interventions that also target engulfment may reduce the risk of increased depressive symptomatology.

Clarifying associations between cortical thickness, subcortical structures, and a comprehensive assessment of clinical insight in enduring schizophrenia.

BACKGROUND: The relationship between poor insight and less favorable outcomes in schizophrenia has promoted research efforts to understand its neurobiological basis. Thus far, research on neural correlates of insight has been constrained by small samples, incomplete insight assessments, and a focus on frontal lobes. The purpose of this study was to examine associations of cortical thickness and subcortical volumes, with a comprehensive assessment of clinical insight, in a large sample of enduring schizophrenia patients. METHODS: Two dimensions of clinical insight previously identified by a factor analysis of 4 insight assessments were used: Awareness of Illness and Need for Treatment (AINT) and Awareness of Symptoms and Consequences (ASC). T1-weighted structural images were acquired on a 3 T MRI scanner for 110 schizophrenia patients and 69 healthy controls. MR images were processed using CIVET (version 2.0) and MAGeT and quality controlled pre and post-processing. Whole-brain and region-of-interest, vertex-wise linear models were applied between cortical thickness, and levels of AINT and ASC. Partial correlations were conducted between volumes of the amygdala, thalamus, striatum, and hippocampus and insight levels. RESULTS: No significant associations between both insight factors and cortical thickness were observed. Moreover, no significant associations emerged between subcortical volumes and both insight factors. CONCLUSIONS: These results do not replicate previous findings obtained with smaller samples using single-item measures of insight into illness, suggesting a limited role of neurobiological factors and a greater role of psychological processes in explaining levels of clinical insight.

Dimensions of insight in schizophrenia: Exploratory factor analysis of items from multiple self- and interviewer-rated measures of insight.

OBJECTIVE: Insight in schizophrenia is regarded as a multidimensional construct that comprises aspects such as awareness of the disorder and recognition of the need for treatment. The proposed number of underlying dimensions of insight is variable in the literature. In an effort to identify a range of existing dimensions of insight, we conducted a factor analysis on combined items from multiple measures of insight. METHOD: We recruited 165 participants with enduring schizophrenia (treated for >3years). Exploratory factor analysis was conducted on itemized scores from two interviewer-rated measures of insight: the Schedule for the Assessment of Insight-Expanded and the abbreviated Scale to assess Unawareness of Mental Disorder; and two self-report measures: the Birchwood Insight Scale and the Beck Cognitive Insight Scale. RESULTS: A five-factor solution was selected as the best-fitting model, with the following dimensions of insight: 1) awareness of illness and the need for treatment; 2) awareness and attribution of symptoms and consequences; 3) self-certainty; 4) self-reflectiveness for objectivity and fallibility; and 5) self-reflectiveness for errors in reasoning and openness to feedback. CONCLUSIONS: Insight in schizophrenia is a multidimensional construct comprised of distinct clinical and cognitive domains of awareness. Multiple measures of insight, both clinician- and self-rated, are needed to capture all of the existing dimensions of insight. Future exploration of associations between the various dimensions and their potential determinants will facilitate the development of clinically useful models of insight and effective interventions to improve outcome.

A pilot study of training and compensation interventions for mild cognitive impairment.

BACKGROUND: This pilot clinical trial sought to estimate the feasibility and efficacy of two interventions aimed at improving memory performance in geriatric clinic patients with mild cognitive impairment. METHODS: Fifteen participants were randomized to either a memory training group or a memory compensation group. RESULTS: Recruitment rates were low, whereas adherence and retention rates were acceptable. The memory training group improved in self-reported memory abilities and satisfaction with memory. The memory compensation group improved on one objective memory test but showed no consistent changes on any other outcomes. CONCLUSION: Effect size estimates will inform the design of larger clinical trials.

Development of a method for quantifying cognitive ability in the elderly through adaptive test administration.

BACKGROUND: The field of geriatric medicine has identified a need for an evaluative tool that can rapidly quantify global cognitive ability and accurately monitor change over time in patients with a wide range of impairments. We hypothesized that the development of an adaptive test approach to cognitive measurement would help to meet that need. This study aimed to provide evidence for the interpretability of scores obtained from a novel, adaptive approach to cognitive assessment, called the Geriatric Rapid Adaptive Cognitive Estimate (GRACE) method. METHODS: An adaptive method for cognitive assessment was developed using data from 185 patients referred for geriatric cognitive assessment, and pilot tested in an additional 137 patients. Correlations between test scores and between rank orders of patients were computed to examine the reliability and validity of cognitive ability scores obtained by (1) administering test questions out of their usual order, (2) administering only a subset of questions, and (3) administering questions adaptively using simplified selection rules based on the most difficult question passed. RESULTS: Cognitive ability scores obtained with the GRACE method correlated highly with the Montreal Cognitive Assessment (MoCA) scores (r = 0.93) and ranked patients similarly in order of ability (r > 0.87). A simplified adaptive testing algorithm for pencil-and-paper assessment demonstrated moderately high correlations with scores obtained from administering the full set of MMSE and MoCA items as well as the MoCA items alone. CONCLUSIONS: Scores from the GRACE method can be obtained easily in 5-10 minutes, reducing test burden. The resulting numeric score quantifies cognitive ability, allowing clinicians to compare patients and monitor change in global cognition over time. The adaptive nature of this method allows for evaluation of persons across a broader range of cognitive ability levels than currently available tests.

Improving precision in the quantification of cognition using the Montreal Cognitive Assessment and the Mini-Mental State Examination.

BACKGROUND: The Montreal Cognitive Assessment (MoCA) can be used to quantify cognitive ability in older persons undergoing screening for cognitive impairment. Although highly sensitive in detecting mild cognitive impairment, its measurement precision is weakest among persons with milder forms of impairment. We sought to overcome this limitation by integrating information from the Mini-Mental State Examination (MMSE) into the calculation of cognitive ability. METHODS: Data from 185 geriatric outpatients screened for cognitive impairment with the MoCA and the MMSE were Rasch analyzed to evaluate the extent to which the MMSE items improved measurement precision in the upper ability ranges of the population. RESULTS: Adding information from the MMSE resulted in a 13.8% (13.3-14.3%) reduction in measurement error, with significant improvements in all quartiles of patient ability. The addition of three-word repetition and recall, copy pentagons, repeat sentence, and write sentence improved measurement of cognition in the upper levels of ability. CONCLUSIONS: The algorithm presented here maximizes the yield of available clinical data while improving measurement of cognitive ability, which is particularly important for tracking changes over time in patients with milder levels of impairment.

French-English cross-linguistic comparison and diagnostic impact of the AD-8 dementia screening questionnaire in a geriatric assessment clinic.

The AD-8 dementia screening questionnaire is a novel tool that allows clinicians to assess changes in cognitive function. This study examined psychometric properties of the test in French-speaking and English-speaking patients, and its impact on diagnostic practice in the geriatric assessment clinics of a university health centre. Data were extracted from the clinical database for all new patients screened for cognitive impairment 15 months before (historic control group) and 15 months after the introduction of the test (AD-8 group and concurrent control group). Analysis of differential item functioning revealed formal equivalence of the French- and English-language items, supporting the validity of the French version. Respondent type significantly influenced the total score on the AD-8. Concurrent validity with other cognitive screening tests was moderately high. Finally, among patients who did not present with pre-existing dementia, a higher proportion of dementia diagnoses was made in those administered the AD-8 relative to the concurrent control group. Implications for clinical use of the AD-8 are discussed.